MBX MBX BIOSCIENCES INC.

MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum

MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum

CARMEL, Ind., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Sam Azoulay, MD, Chief Medical Officer, will participate in a fireside chat at the Stifel 2025 Virtual Cardiometabolic Forum on September 30.

Stifel 2025 Virtual Cardiometabolic Forum

Date: Tuesday, September 30, 2025

Format: Fireside chat

Time: 10:00 a.m. – 10:25 a.m. ET

Location: Virtual

The live webcast of the presentation can be accessed in the events sections of MBX’s website at Access to the webcast replay will be available approximately two hours after the completion of the event and will be archived on the Company’s website for approximately 90 days.

About MBX Biosciences 

MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism (HP) in Phase 2 development; imapextide (1416) for the treatment of post-bariatric hypoglycemia (PBH) in Phase 2 development; and an obesity portfolio that includes MBX 4291 in Phase 1 development, as well as multiple discovery and pre-clinical obesity candidates. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at and follow it on .

Media Contact:

Katie Beach Oltsik

Inizio Evoke Comms

   

(937) 232-4889

Investor Contact:

Jim DeNike

MBX Biosciences



EN
29/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MBX BIOSCIENCES INC.

 PRESS RELEASE

MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabo...

MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum CARMEL, Ind., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Sam Azoulay, MD, Chief Medical Officer, will participate in a fireside chat at the Stifel 2025 Virtual Cardiometabolic Forum on September 30. Stifel 2025 Virtual Cardiometa...

 PRESS RELEASE

MBX Biosciences Announces Pricing of Upsized Public Offering

MBX Biosciences Announces Pricing of Upsized Public Offering CARMEL, Ind., Sept. 24, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the pricing of its upsized public offering of 11,108,055 shares of its common stock at a price to the public of $18.00 per share. The gross proceeds to MBX Biosciences from the offering, before deducting underwriting discounts and commissions and other of...

 PRESS RELEASE

MBX Biosciences Announces Proposed Public Offering

MBX Biosciences Announces Proposed Public Offering CARMEL, Ind., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed underwritten public offering of 10,000,000 shares of its common stock. Furthermore, MBX Biosciences intends to grant the underwriter...

 PRESS RELEASE

MBX Biosciences to Provide Topline Results from its Phase 2 Trial of P...

MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22 CARMEL, Ind., Sept. 19, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it will provide topline results from its Phase 2 clinical trial of potential once-weekly canvuparatide for patients with chronic hypoparathyroidism (HP) a...

 PRESS RELEASE

MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 f...

MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity Preclinical data support the potential for improved weight loss and tolerability with once-monthly administration of MBX 4291 CARMEL, Ind., Sept. 04, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced dosing of the first participant in its Phase 1 trial of MBX 4291, the Company’s Precision ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch